IsoRay Is Set For Further Growth
IsoRay’s proprietary Cesium-131 based therapies have cost, effectiveness and side effect advantages, which are leading to increased application. It is still in the early innings of capturing an increasing market. […]
IsoRay Likely Has Further To Rise
The company’s Cesium-131 based cancer treatments are effective, cheap and produce less side effects than other radiation. The company’s market cap is small in relation to its first big target […]
IsoRay Has Exciting Prospects
The shares of the cancer therapy producer were buffeted by FDA approval and dilution. Their Cesium-131 based brachytherapy solutions show a lot of promise, not only in combating prostate cancer […]